Health authorities around the world define “Cancer” as a life-threatening disease. This definition suits our intuitive definition. The meaning of a “life-threatening disease” is that the person, who has this disease, is in real danger to his life as long as he is ill. He lives in mortal danger.
From the definition of cancer, the therapeutic goals are detailed according to the condition of the disease and these can be:
- Saving lives – relevant, for example, when the patient is diagnosed at very early stages of the disease. The standard protocols usually achieve this goal.
- Life prolongation – in the following two situations separately or in combination:
- Metastatic disease, whether at the time of diagnosis or later when the disease progressed, such as metastatic breast cancer, metastatic lung cancer, metastatic colorectal cancer, metastatic ovarian cancer and more.
- An aggressive type of cancer, such as glioblastoma (GBM), pancreatic cancer, melanoma, stomach cancer and more.
- Preserve and improve patient quality of life.
TRIAL-IN Pharma is focused on addressing both therapeutic goals: extending life and preserving and improving the quality of life.
Time is a critical and significant resource for metastatic cancer patients and / or aggressive cancers. It is a more aggressive disease, develops resistance to different treatments and these patients do not always have a supply of standard treatments. It is important to learn about as many treatment options as possible in order to receive the best treatment. Patients and their relatives must be active in obtaining information. It is important that they make the right decisions. It is important that they be involved in the process of choosing the treatments. It is important that they replace thoughts such as “I cannot, I do not have the tools” or “I must not interfere with the doctor” and “I feel it’s not appropriate” with thoughts like “I can and must act, and it does not matter to me what someone – no matter how senior – will tell me about it, for good or for bad.” You have to realize and accept that you cannot please everyone when there is no time and most importantly it is to help the patient receive the best treatment. The choice to be active from the moment of diagnosis has been reported in the literature as increasing the survival of cancer patients regardless of the treatment chosen.
The vast majority of cancer treatments offered to cancer patients at medical centers adhere to the standard protocols, whose success rates have been studied and known.
But when it comes to metastatic cancer patients and / or patients with particularly aggressive cancer, the known standard protocols, however good they may be, are not enough to achieve the primary goal of both life prolongation and quality of life and it is necessary to check which other treatments may achieve the goals much better than any standard treatment.
It is important to know that there are currently available, advanced and at the forefront of science treatments around the world that a cancer patient may gain beyond any standard protocol and due to system limitations, these options are missed under the radar, so that the patient and his relatives often do not know about them at all.
When building a treatment plan with the oncologist, you must exhaust all the options and make sure that the oncologist has all the information about them. This is the responsibility of the patient and his relatives, if you do not find out for yourself – you will not know. You are the ones who need to take the reins of information and not just rely on the system. In some way, you must help and support the medical system – this may change the whole course of your illness and your life. Your oncologist sees up to 20 patients a day of work, the load is indescribable and the time spent answering patient needs is very limited. We are here to help you strengthen and empower the ability of your oncologist to choose the best treatment for you.
Cancer is a complex disease, and patients are different from each other even if they have the same type of tumor. However, the development of cancer drugs has become smarter than in the past in light of the accumulated information about the disease and the mechanisms involved in its development. As evidence, in recent years we have seen more and more breakthroughs and more FDA approvals for the introduction of cancer drugs into an “accelerated track”.
For metastatic cancer patients, it is important to know about the possibility of receiving treatment combining two types of immunotherapy, which may increase their independently success rates from 20-30% to 60-70%. This is one of many examples of advanced treatment beyond standard, who would not want an opportunity to receive it? Who would not want to have such a chance six or seven years before the combined treatment would receive worldwide approval and then become the most acceptable treatment?
Who is our test for?
- For metastatic cancer patients, for example, metastatic breast cancer, metastatic lung cancer, metastatic colorectal cancer, metastatic ovarian cancer;
- For cancer patients with a particularly aggressive type of cancer, such as glioblastoma (GBM), pancreatic cancer, melanoma, gastric cancer;
- And in any progression of the disease.
And especially, those cancer patients and families who are unwilling to accept the statistics, who understand and want to be active, involved, want to take control and responsibility for the treatments offered to them, those who are unwilling to give up and are ready to set out, trying hard to reach the ultimate remedy even though the medical system will not always support them, but they understand very well that the goal justifies the means.
Important note! Our service is not intended for hematologic patients (different types of blood cancer).
Personalized matching for every patient
In the first stage, we receive the patient’s medical record or relevant documents from it and study in depth the patient’s condition and the characteristics of his tumor.
The report’s findings include:
- Worldwide clinical trials that the patient is eligible for and best matched the patient’s specific medical condition.
- Worldwide compassionate treatments relevant to the patient.
- Review literature especially in cases of rare tumors and with the goal of finding case reports similar to the patient in which it was reported that the provision of a certain treatment resulted in impressive therapeutic results.
- Information on other treatments that we think may also increase the success rate of treatment.
- In addition, we insert links to the details of the treatments specified in the report and it is important to enter these links and learn about the clinical trials, review professional publications appropriate to the case, have details of the contact persons regarding the treatment, including their email addresses and telephone number and any other information in the report which we find relevant to the patient.
The world has about 20,000 cancer clinical studies (“clinical trial” is a study in which humans receive treatment) open to cancer patients and in each country a few are available, if at all, in a specific medical center.
We, at TRIAL-IN Pharma, process this vast information of the clinical trials and criteria of each one of them, with the patient’s medical record, navigating and identifying the same studies that the patient meets its criteria, flooding and exposing them to the cancer patient and the treating oncologist at the medical center. This is a process that takes two to three weeks of work on each individual patient.
To date, we have exposed personalized treatments to all dozens of cancer patients who have contacted us, 100% success!
In the second stage, during the patient’s visit to the oncologist at the medical center, a discussion is held between them about all the therapeutic options for selecting the best treatment, which is best suited to the patient’s condition and the characteristics of the illness. An oncologist now has the complete information required for him and beyond his knowledge of standard protocols. Before this important visit, we prepare you and kindly explain the findings in the report so that you will come equipped with the maximum amount of information for this visit, and it is important for us you understand the findings as much as possible in order for you to be involved in the choice of treatment.
This choice can change the entire course of the disease and your life, it is in your hands.
It is important to note that the oncologist plays a crucial role in the choice of treatment since he is familiar with the patient better than everyone else. Therefore, the report should not be regarded as a therapeutic recommendation but rather as personalized information on treatments beyond the standard protocols.
The third stage is the stage in which we work to make the chosen treatment accessible to the patient in order to receive it. We open a channel of communication with medical centers around the world, research teams, leading researchers, senior oncologists, and pharmaceutical companies. We make sure to translate the medical documents, update the oncologist and the patient if additional tests are needed before receiving the treatment, and make sure that we receive an answer to our requests and to the extent possible, we support bringing the treatment to the place where the patient resides.